1. Name and Address of Reporting Person
   Murphy Nicole
   (Last)              (First)            (Middle)
   225 BINNEY STREET
   (Street)
   CAMBRIDGE MA 02142
   (City)              (State)           (Zip)

2. Issuer Name and Ticker or Trading Symbol
   BIOGEN INC. [ BBIIB ]

3. Date of Earliest Transaction (Month/Day/Year)
   08/01/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)
   08/01/2022

5. Relationship of Reporting Person(s) to Issuer
   (Check all applicable)
   Director
   X 10% Owner
   Officer (give title below)
   Head of Pharm Ops and Tech
   Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

---

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/01/2022</td>
<td></td>
<td>M</td>
<td>255 A</td>
<td>2,170,2903 (1)</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/01/2022</td>
<td></td>
<td>F</td>
<td>76 D</td>
<td>2,094,2903</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/01/2022</td>
<td></td>
<td>M</td>
<td>825 A</td>
<td>2,919,2903</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/01/2022</td>
<td></td>
<td>F</td>
<td>243 D</td>
<td>2,676,2903</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

---

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Unit</td>
<td>$0</td>
<td>08/01/2022</td>
<td></td>
<td>M</td>
<td>255 (3)</td>
<td>299 Common Stock $0 255 D</td>
<td></td>
<td>M</td>
<td>825 $0 0 D</td>
<td>M</td>
<td></td>
</tr>
<tr>
<td>Restricted Stock Unit</td>
<td>$0</td>
<td>08/01/2022</td>
<td></td>
<td>M</td>
<td>255 (3)</td>
<td>255 Common Stock $0 0 D</td>
<td></td>
<td>M</td>
<td>255 $0 0 D</td>
<td>M</td>
<td></td>
</tr>
<tr>
<td>Restricted Stock Unit</td>
<td>$0</td>
<td>08/01/2022</td>
<td></td>
<td>M</td>
<td>255 (4)</td>
<td>285 Common Stock $0 0 D</td>
<td></td>
<td>M</td>
<td>825 $0 0 D</td>
<td>M</td>
<td></td>
</tr>
</tbody>
</table>

---

**Explanation of Responses:**

1. Includes 102,4003 shares acquired under the Biogen Inc. employee stock purchase plan.
2. This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
3. This award was granted to the reporting person on August 1, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date).
4. This award was granted to the reporting person on August 1, 2019 and vested in full on August 1, 2022.

/s/ Wendell Taylor, attorney in fact for Nicole Murphy 08/03/2022

**Signature of Reporting Person**

**Date**

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.